<?xml version="1.0" encoding="UTF-8"?>
<TEI xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 C:\PWang\Datasets\grobid-0.5.5\grobid-0.5.5\grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<encodingDesc>
			<appInfo>
				<application version="0.5.5" ident="GROBID" when="2020-06-22T14:05+0000">
					<ref target="https://github.com/kermitt2/grobid">GROBID - A machine learning software for extracting information from scholarly documents</ref>
				</application>
			</appInfo>
		</encodingDesc>
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Kingdom of Saudi Arabia, 2 King Abdullah International Medical Research Centre</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>ID</roleName><forename type="first">Amir</forename><surname>Abushouk</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Basic Medical Sciences</orgName>
								<orgName type="department" key="dep2">College of Medicine</orgName>
								<orgName type="department" key="dep3">Department of Basic Medical Sciences</orgName>
								<orgName type="department" key="dep4">College of Medicine</orgName>
								<orgName type="department" key="dep5">Department of Medical Education</orgName>
								<orgName type="department" key="dep6">College of Medicine-Riyadh</orgName>
								<orgName type="laboratory">King Saud Bin Abdul-Aziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia, 4 Research Unit</orgName>
								<orgName type="institution">University for Health Sciences</orgName>
								<address>
									<addrLine>King Saud Bin Abdul-Aziz, Kingdom of Saudi Arabia</addrLine>
									<settlement>Riyadh</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Amre</forename><surname>Nasr</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Emad</forename><surname>Masuadi</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gamal</forename><surname>Allam</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Microbiology and Immunology</orgName>
								<orgName type="department" key="dep2">College of Medicine</orgName>
								<orgName type="department" key="dep3">Department of Zoology</orgName>
								<orgName type="department" key="dep4">Faculty of Science</orgName>
								<orgName type="institution">Taif University</orgName>
								<address>
									<addrLine>Saudi Arabia, 6 Immunology Section</addrLine>
									<settlement>Taif</settlement>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution">Beni-Suef University</orgName>
								<address>
									<settlement>Beni-Suef</settlement>
									<country key="EG">Egypt</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Emmanuel</forename><forename type="middle">E</forename><surname>Siddig</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Mycetoma Research Centre</orgName>
								<orgName type="institution">University of Khartoum</orgName>
								<address>
									<settlement>Khartoum</settlement>
									<country key="SD">Sudan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ahmed</forename><forename type="middle">H</forename><surname>Fahal Id</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Mycetoma Research Centre</orgName>
								<orgName type="institution">University of Khartoum</orgName>
								<address>
									<settlement>Khartoum</settlement>
									<country key="SD">Sudan</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Kingdom of Saudi Arabia, 2 King Abdullah International Medical Research Centre</title>
					</analytic>
					<monogr>
						<title level="j" type="main">National Guard Health Affairs</title>
						<meeting> <address><addrLine>Jeddah; Riyadh, Kingdom of Saudi Arabia</addrLine></address>
						</meeting>
						<imprint>
							<biblScope unit="page">3</biblScope>
						</imprint>
					</monogr>
					<note>RESEARCH ARTICLE</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Abstract</head><p>Mycetoma is a neglected tropical disease, endemic in many tropical and subtropical regions, characterised by massive deformity and disability and can be fatal if untreated early and appropriately. Interleukins (IL) -35 and IL-37 are newly discovered cytokines that play an important role in suppressing the immune system. However, the expression of these interleukins in patients with Madurella mycetomatis (M. mycetomatis) induced eumycetoma has not yet been explored. The aim of this study is to determine the levels of IL-1 family (IL-1β, IL-37) and IL-12 family (IL-12, IL-35) in a group of these patients and the association between these cytokines levels and the patients' demographic characteristics. The present, case-control study was conducted at the Mycetoma Research Centre, Soba University Hospital, University of Khartoum, Sudan and it included 140 individuals. They were divided into two groups; group I: healthy controls [n = 70; median age 25 years (range 12 to 70 years)]. Group II: mycetoma patients [n = 70 patients; median age 25 (range 13 to 70 years)]. Cytokines levels were measured in sera using enzyme linked immunosorbent assay (ELISA). There was a significant negative correlation between IL-1β and IL-12 levels and lesion size and disease duration, while IL-37 and IL-35 levels were significantly positively correlated with both lesion size and disease duration. The analysis of the risk factors of higher circulatory levels of IL-37 in patients of mycetoma showed a negative significant association with IL-1β cytokine, where a unit increment in IL-1β will decrease the levels of IL-37 by 35.28 pg/ ml. The levels of IL-37 among the patients with a duration of mycetoma infection � 1 year were significantly low by an average of 18.45 pg/ml compared to patients with a mycetoma infection's duration of � 5years (reference group). Furthermore, the risk factors of higher levels of IL-35 in mycetoma patients revealed a negative significant association with IL-12, as a unit increment in IL-12 decreases the levels of IL-35 by 8.99 pg/ml (p &lt; 0.001). Levels of IL-35 among the patients with duration of mycetoma infection � one year were significantly low on average by 41.82 pg/ml (p value = 0.002) compared to patients with a duration of mycetoma infection � 5 years (reference group). In conclusion, this study indicates that both IL-35 and IL-37 are negatively associated with the levels of IL-1β and IL-12 in eumycetoma mycetoma infection; and high levels of IL-37 and IL-35 may have a negative impact on disease progression.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Author summary</head><p>Mycetoma is a progressive chronic granulomatous fungal or bacterial infection that may result in massive destruction of subcutaneous tissues, muscles and bones. Mycetoma is a neglected disease which is endemic in many tropical and subtropical areas. If the disease is not treated properly, eventually it ends up with amputation and adverse medical, health and socioeconomic effects on patients and the community. Previous data suggested a crucial role of adaptive immunity in host resistance to causative agents and in the disease progress. The recently identified IL-35 and IL-37 cytokines revealed an important role in immune suppression. Nevertheless, the expression of these interleukins in patients with mycetoma has not yet been investigated. Therefore, the present case-control study aimed to determine the levels of IL-1 family (IL-1β, IL-37) and IL-12 family (IL-12, IL-35) in these patients and the association between these cytokines levels and the patients' demographic characteristics. The results of this study showed that, the levels of IL-37 and IL-35 were consistently positively correlated with different diameters of mycetoma lesions as well as its duration. However, the levels of IL-1β and IL-12 were consistently negatively correlated with different diameters of lesions and the duration of mycetoma infection. The analysis of the risk factors of higher circulatory levels of IL-37 in patients of mycetoma showed a negative significant association with IL-1β cytokine Furthermore, the risk factors of higher levels of IL-35 in patients of mycetoma revealed a negative significant association with IL-12. These findings uncover a possible the role of IL-35 and IL-37 in the pathogenesis of mycetoma, and may declare their potential value in treatment of mycetoma.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><formula xml:id="formula_0">a1111111111 a1111111111 a1111111111 a1111111111 a1111111111</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>Mycetoma is a chronic granulomatous subcutaneous inflammatory disease, caused by certain bacteria (actinomycetoma) or fungi (eumycetoma). This infection progresses to affect the deep structures and bones leading to massive destruction, deformities and disabilities <ref type="bibr" target="#b0">[1]</ref>. It constitutes a major health problem in many tropical and subtropical countries and it is highly endemic in Sudan, Mexico, and India. In Sudan, more than 8500 patients were managed at the Mycetoma Research Centre in Khartoum, of whom 70% were infected with the fungus M. mycetomatis. The disease affects all age groups, but it occurs most commonly in young men at the age group 20 to 40 years <ref type="bibr" target="#b1">[2]</ref>. The disease is usually painless and the clinical diagnosis is commonly based on the presence of subcutaneous mass, multiple sinuses and seropurulent discharge with grains. Treatment opportunities comprise of various chemotherapeutics agents and wide surgical excision of the infected tissues and may possibly end up with limb amputation <ref type="bibr" target="#b2">[3]</ref>.</p><p>Although most individuals in endemic areas have antibodies against the causative agent of mycetoma; only few develop the disease <ref type="bibr" target="#b3">[4]</ref>. Both innate and adaptive immunity play a role in host resistance to causative agents and in the development of disease. Therefore, T-cell responses seem to be important in the progress of mycetoma <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref>. A T-helper (Th) 2-like response was reported in primary lesions and in draining lymph nodes in patients with Streptomyces somaliensis infection and after stimulation of peripheral blood mononuclear cells by M. mycetomatis antigens <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b6">7]</ref>, whilst Th1 response was reported in the acute phase of infection and in healthy endemic controls <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b8">9]</ref>. Macrophages stimulated with live conidia of Pseudallescheria boydii also induced a Th2 response, whereas hyphae induced a Th1 response <ref type="bibr" target="#b9">[10]</ref>. Experimental infection of nude athymic rats and mice with Nocardia (N.) asteroids let to fatal disease dissemination <ref type="bibr" target="#b10">[11,</ref><ref type="bibr" target="#b11">12]</ref>. In addition, T lymphocytes from previously immunised animals directly killed N. asteroides <ref type="bibr" target="#b11">[12,</ref><ref type="bibr" target="#b12">13]</ref>. Moreover, Trevino-Villarreal and associates <ref type="bibr" target="#b13">[14]</ref> reported that N. brasiliensis cell wall-associated lipids are implicated in the development of experimental actinomycetoma and act principally by inhibiting several microbicidal effects of macrophages, including the inhibition of TNF-α production, phagocytosis, production of nitric oxide (NO), and bacterial killing. In addition, they demonstrated that the N. brasiliensis wall-associated lipids suppressed the expression of major histocompatibility complex class II (MHC II), CD80, and CD40 by dendritic cells (DCs) and strongly induced the production of TGF-β by these cells. It has been suggested that pre-existing Th2 environment caused by schistosomiasis promotes the development of mycetoma as patients with mycetoma were significantly more positive for schistosoma antibodies than healthy endemic controls <ref type="bibr" target="#b8">[9]</ref>. These findings suggested that Th2 like response and anti-inflammatory/immunosuppressive cytokines could have a negative impact on mycetoma development and disease progression.</p><p>IL-1 is a polypeptide which has two forms; IL-1α and IL-1β. It is involved in the acutephase response and is accountable for several alterations that are related to the onset of various medical disorders <ref type="bibr" target="#b14">[15,</ref><ref type="bibr" target="#b15">16]</ref>. It is demonstrated recently that higher levels of IL-1β cytokine are strongly associated with surgically treated mycetoma patients, in comparison to those treated without surgery <ref type="bibr" target="#b16">[17]</ref>. It is known that IL-1β is a pro-inflammatory cytokine that is involved in cell death coordination <ref type="bibr" target="#b17">[18]</ref>. IL-1β cytokine is cleaved into the mature, active form primarily by inflammasome dependent caspase activity <ref type="bibr" target="#b17">[18]</ref>. It is possibly that mature IL-1β secretion by macrophages activates IL-1 receptor type 1 (IL-1R1) on macrophages, fibroblasts and epithelial cells, inducing production of the CXC chemokine CXCL1/KC, which binds to CXCR2 on neutrophils and mediates recruitment of neutrophils from peripheral blood to stimulate inflammation at the site of mycetoma invasion. Therefore, these higher levels of IL-1β cytokine advocate a crucial role in M. mycetomatis pathogenesis.</p><p>IL-37, which is a member of the IL-1 family, has emerged as a potent anti-inflammatory cytokine that suppresses both innate and adaptive immune responses <ref type="bibr" target="#b18">[19]</ref>. Its role in human diseases is not completely understood yet <ref type="bibr" target="#b19">[20]</ref>. However, the anti-inflammatory properties of IL-37 have been associated with inflammatory diseases, such as systemic lupus erythematosus (SLE) <ref type="bibr" target="#b20">[21]</ref>, and inflammatory bowel disease <ref type="bibr" target="#b21">[22]</ref>. It has been reported that IL-37 is negatively associated with pro-inflammatory cytokines such as IL-1β, IL-6, IL-17, TNF-α and IFN-γ in peripheral blood mononuclear cells (PBMCs) of patients with degenerative intervertebral discs <ref type="bibr" target="#b22">[23]</ref> and Graves' disease (GD) <ref type="bibr" target="#b23">[24]</ref>. IL-37 protein level in PBMCs and DCs is up-regulated when stimulated by Toll-like receptor (TLR) ligands or pro-inflammatory cytokines <ref type="bibr" target="#b24">[25]</ref>. In vitro, over expression of IL-37 in macrophages or epithelial cells greatly inhibits the production of major pro-inflammatory cytokines such as TNF-α, IL-1α, IL-1β, IL-6, IFN-γ and macrophage inflammatory protein 2 <ref type="bibr" target="#b24">[25,</ref><ref type="bibr" target="#b25">26]</ref>. In vivo, IL-37 transgene protects mice from lipopolysaccharides-induced shock and chemical-induced colitis <ref type="bibr" target="#b18">[19,</ref><ref type="bibr" target="#b26">27]</ref>. IL-37 interferes with the innate protective anti-Candida host response by reducing the production of pro-inflammatory cytokines and suppressing neutrophil recruitment in response to Candida infection, resulting in an increased susceptibility to disseminated candidiasis <ref type="bibr" target="#b27">[28]</ref>. Moreover, IL-37 markedly reduced inflammasome activation and disease severity in murine aspergillosis <ref type="bibr" target="#b28">[29]</ref>. In addition to its role in innate immunity; IL-37 plays a pivotal role in regulating adaptive immunity by inducing T regulatory (T reg ) cells and impairing activation of effector T-cell responses <ref type="bibr" target="#b29">[30]</ref>. To our knowledge, there has been no study to report the relationship between IL-37 and mycetoma pathogenesis so far.</p><p>Interleukin-12 (IL-12) is frequently denoted as a B cell cytokine, although it is mainly formed by innate immune cells, comprising epithelial cells, DCs, and macrophages <ref type="bibr" target="#b30">[31]</ref>. IL-12 is a multimer that plays a fundamental role in immune regulation and is extensively involved in infections. It binds to the heterodimeric IL-12 receptor, which is principally present in T cells and on natural killer (NK) cells <ref type="bibr" target="#b30">[31]</ref>. IL-12 induces Th1 responses <ref type="bibr" target="#b31">[32]</ref>, which consequently increase the cytotoxic cytokines, in addition to IFN-γ by T cells <ref type="bibr" target="#b30">[31,</ref><ref type="bibr" target="#b31">32]</ref>.</p><p>IL-35 is a recently identified heterodimeric cytokine which belongs to the IL-12 cytokine family, composed of the subunits of IL-27; β chain Epstein-Barr-virus (EBV)-induced gene 3 (Ebi3) and IL-12α chain p35 <ref type="bibr" target="#b32">[33,</ref><ref type="bibr" target="#b33">34]</ref>. IL-35 is a potent immunosuppressive cytokine produced by B regulatory cells (B reg ) <ref type="bibr" target="#b34">[35]</ref>, DCs <ref type="bibr" target="#b35">[36]</ref>, and to a lesser extent, by endothelial cells, smooth muscle cells, and monocytes <ref type="bibr" target="#b36">[37]</ref>. The biological effect of IL-35 is poorly understood, however IL-35 is recognised as a typical anti-inflammatory cytokine, and the predominant mechanism of suppression is associated with its ability to suppress T cell proliferation and effector functions <ref type="bibr" target="#b32">[33,</ref><ref type="bibr" target="#b37">38]</ref>. Given the direct immunosuppressive effect of IL-35, many studies have been conducted to evaluate its role in the development of several diseases. IL-35 can suppress several types of chronic inflammatory diseases such as inflammatory bowel disease <ref type="bibr" target="#b25">[26]</ref>, and decreased the severity of collagen induced arthritis in animals via enhancement of IL-10 production <ref type="bibr" target="#b38">[39]</ref> and suppression of Th17 cells <ref type="bibr" target="#b39">[40]</ref>. In an asthma model, intra-tracheal instillation of IL-35 decreased disease severity by diminishing the Th2 cell counts <ref type="bibr" target="#b40">[41]</ref> and by reducing the production of IL-17 <ref type="bibr" target="#b41">[42]</ref>. In bacterial infections, Shen and associates <ref type="bibr" target="#b34">[35]</ref> found that mice without IL-35 expression demonstrated an obviously improved resistance to infection with the intracellular bacterial pathogen Salmonella typhimurium. In addition, IL-35 has been increased in the serum of adults and children with sepsis, and administration of anti-IL-35 p35 antibodies diminished dissemination of the bacteria in septic animals <ref type="bibr" target="#b42">[43]</ref>. Similarly, tuberculous patients exhibited an increase in serum IL-35 and in mRNA expression of both subunits of IL-35 (p35 and EBI3) in white blood cells and peripheral blood mononuclear cells <ref type="bibr" target="#b43">[44]</ref>. However, the role of IL-35 in mycetoma pathogenesis has not been highlighted yet.</p><p>With this background this study was set to determine the IL-1 cytokine family (IL-1β, IL-37) and IL-12 cytokine family (IL-12, IL-35) circulating levels of in patients infected with M. mycetomatis, and to explore the association between the pro-inflammatory/anti-inflammatory cytokine levels and the patients' demographic characteristics. This is correlation may help to understand the pathogenesis of mycetoma disease.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study population</head><p>This case-control study was conducted at the Mycetoma Research Centre, Soba University Hospital, University of Khartoum, Sudan. After a written informed consent, blood samples were taken from patients and a matched control population living in the mycetoma endemic areas of Sudan between 2015 and 2016. Samples collection was previously described in details by Nasr and associates <ref type="bibr" target="#b16">[17]</ref>.</p><p>In this study 140 individuals were enrolled; 49 (35%) were females and 91 (65%) were males with an overall median age of 25 years (range 12-70 years). Seventy patients were infected with M. mycetomatis. The study population was divided into two groups; group I: healthy controls [n = 70; median age 25 years (range 12 to 70 years)]. Group II: mycetoma patients [n = 70 patients; median age 25 (range 13 to 70 years)]. Both groups had a similar gender distribution, 54 (80%) were males in each group.</p><p>The diagnosis of eumycetoma was established by various techniques and that included imaging, molecular and histopathological techniques, and grain culture <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b44">45]</ref>. Surgical biopsies are obtained by a wide local incision under anaesthesia and appropriate surgical conditions as part of the routine patients' treatment protocol <ref type="bibr" target="#b44">[45]</ref>.</p><p>After medical examination, healthy controls were selected from blood bank donors or healthy volunteers to match the patient's birthplace geographically. All healthy controls were questioned for acute or chronic infectious diseases, autoimmune family history and genetic disorders. Then all study participants gave their informed written consent and the study was approved by the Ethics Committee of the Faculty of Medicine, University of Khartoum, Sudan.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sample collection</head><p>One hundred μl of blood were collected on Whatman qualitative filter paper, Grade 1, circles, diam. 42.5 mm (Sigma-Aldrich Chemical Co., St. Louis, MO, USA) for determination of cytokines. The use of filter paper dried whole blood spots (DBS) for specimen collection was preferred to facilitate collection, storage and transportation of specimens and it is in line with the World Health Organization recommendations and also used in several previous studies <ref type="bibr" target="#b45">[46]</ref><ref type="bibr" target="#b46">[47]</ref><ref type="bibr" target="#b47">[48]</ref>. Sera were extracted from filter-paper samples as described previously in details <ref type="bibr" target="#b16">[17]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>IL-1β, IL-37, IL-12 and IL-35 estimation</head><p>IL-1β, IL-37, and IL-12 were measured in the sera using commercially available enzyme linked immunosorbent assay (ELISA) kits (Abcam, Cambridge, UK). Serum levels of IL-35 were estimated using a sandwich ELISA commercial kit (Colorful Gene Biological Technology, Wuhan, China). Cytokine assays were performed in duplicates according to the manufacturers' protocols. The sensitivity of Human ELISA kits for IL-1β, IL-37, IL-12 and IL-35 cytokines was 0.5 pg/ml.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p>The data were managed by SPSS version 24.0 statistical software for Windows (IBM SPSS statistics) and appropriate statistical tests were used. The results are expressed as mean ± standard deviation (SD) or median with interquartile range (IQR). Spearman correlation test was used to evaluate the associations between serum IL-37 and IL-35 levels and laboratory values as well as serum cytokine levels. For non-parametric data, comparisons between the groups were performed using the Kruskal-Wallis test. One-way ANOVA was used for parametric data. General linear models were used to assess the risk factors for circulating IL-37 and IL-35 among mycetoma patients with different disease duration and lesions size of mycetoma infection adjusted with other variables. A test with a p value &lt;0.05 was considered statistically significant.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethical considerations</head><p>This study was approved by the Ethics Committee of Soba University Hospital, Khartoum, Sudan (SUH, EC-17-029). Written informed consent was taken from all the participants before enrolment in the study. The work described here was performed in accordance with the Declaration of Helsinki <ref type="bibr" target="#b48">[49]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p>This study included 70 confirmed mycetoma patients and 70 healthy controls; gender and age matched. Fifty-six patients (80%) were males and 14 (20%) were females. Their ages ranged between 12 and 77 years and the median age was 25.5 years. The common age group <ref type="bibr">[</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Correlations between cytokine levels (IL-1β, IL-37, IL-12 and IL-35) stratified by the lesion diameter among mycetoma patients and control group</head><p>The levels of cytokines (IL-1β, IL-37, IL-12 and IL-35) were constitutively correlated among mycetoma patients with different lesions diameters. The levels of IL-1β were constitutively positively correlated with IL-12 and lesions diameter ( <ref type="table" target="#tab_2">Table 2)</ref>. On the other hand, the levels of cytokine IL-1β were constitutively negatively correlated with IL-37 and IL-35 <ref type="table" target="#tab_2">(Table 2)</ref>. Furthermore, the levels of cytokine IL-37 were constitutively positively correlated with IL-35 ( <ref type="table" target="#tab_2">Table 2)</ref>. However, the levels of cytokine IL-37 and IL-35 were constitutively negatively correlated with IL-12 ( <ref type="table" target="#tab_2">Table 2)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Correlations between cytokine levels (IL-1β, IL-37, IL-12 and IL-35) stratified by the disease duration and control group</head><p>In the patients group, the levels of cytokines (IL-1β, IL-37, IL-12 and IL-35) were constitutively correlated with the duration of mycetoma infection. Levels of IL-1β showed a consistent positive correlation with IL-12 and negative correlation with IL-37 and IL-35 <ref type="table" target="#tab_3">(Table 3)</ref>. Whereas, levels of IL-37 were constitutively positively correlated with IL-35 <ref type="table" target="#tab_3">(Table 3)</ref>. However, the levels of IL-37 and IL-35 were constitutively negatively correlated with IL-12 ( <ref type="table" target="#tab_3">Table 3)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Analysis of the serum levels of IL-1β, IL-37, IL-12 and IL-35 within the different lesion diameters among mycetoma patients and control groups</head><p>Circulating serum cytokine levels were determined in all mycetoma patients and were compared between the different lesion diameters among mycetoma patients and healthy controls. Overall, there was a significant difference in the levels of all studied cytokines between the four groups (Three levels of lesion diameter and the healthy controls), <ref type="table" target="#tab_4">(Table 4)</ref>. Distribution of IL-1β levels has decreased dramatically with lesion diameter [for lesion diameter � 5 cm: the mean ± SD (3.39 ± 1.07); for 5-10 cm: (2.32 ± 0.05); for � 10 cm: (2.08 ± 0.11), p value &lt; 0.001]. However, the circulating serum levels of IL-37 were significantly increased with lesion diameter [for lesion diameter � 5 cm: the mean ± SD (107.92 ± 5.96); for 5-10 cm: (141.45 ± 12.96) and for � 10 cm: (193.20 ± 15.01), p value &lt; 0.001], <ref type="table" target="#tab_4">(Table 4)</ref>.</p><p>Our results showed a significant reduction of circulating IL-12 levels versus lesion diameter [for lesion diameter � 5 cm: the mean ± SD (25.22±3.34); for 5-10 cm: (14.45± 3.32); for � 10 cm: (9.65 ± 0.36), p value &lt; 0.001], <ref type="table" target="#tab_4">(Table 4)</ref>. Circulating levels of IL-35 were significantly increased with increasing lesions' diameter [for lesion diameter � 5 cm: the mean ± SD (255.15 ± 1.72); for 5-10 cm: (263.23 ± 3.26); � 10 cm: (449.71 ± 22.2), p value &lt; 0.001], <ref type="table" target="#tab_4">(Table 4)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Analysis of the serum levels of IL-1β, IL-37, IL-12 and IL-35 among mycetoma patients stratified by different durations of mycetoma infection compared to the control group</head><p>Circulating levels of IL-1β had significantly decreased with increasing disease duration [(� 1 year; median = 2.3 pg/ml), (2-4 years; median = 2.2 pg/ml) and (� 5 years; median = 2.2 pg/ ml)], p value = 0.017 <ref type="table" target="#tab_5">(Table 5</ref>). Serum levels of IL-12 dramatically decreased with the increase in disease duration [(� 1 year; median = 12.5 pg/ml), (2-4 years; median = 10.2 pg/ml) and (� 5 years; median = 9.8 pg/ml)] and p value &lt; 0.001 <ref type="table" target="#tab_5">(Table 5)</ref>. However, circulating levels of IL-37 were positively increased with different durations of mycetoma infection [(� 1 year; median = 145 pg/ml), (2-4 years; median = 178 pg/ml) and (� 5 years; median = 185.2 pg/ ml)], p value &lt;0.001 <ref type="table" target="#tab_5">(Table 5)</ref>. Similarly, serum levels of IL-35 were also significantly increased with increasing duration of mycetoma infection [(� 1 year; median = 262.5 pg/ml), (2-4 years; median = 423.5 pg/ml) and (� 5 years; median = 436 pg/ml)], p value &lt; 0.001 <ref type="table" target="#tab_5">(Table 5)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Risk factors for increased IL-37 levels in mycetoma patients with different lesion diameters</head><p>The analysis of the risk factors of higher levels of IL-37 in patients of mycetoma showed a significant negative association with IL-1β, where a unit increment in IL-1β decreases the levels  of IL-37 by 9.1 pg/ml, p value = 0.008 <ref type="table" target="#tab_6">(Table 6</ref>). Serum levels of IL-37 among the patients with lesion diameter � 5 cm and 5-10 cm have significantly lower on average by 75.4% and 52.6%, respectively, compared to patients with lesion diameter � 10 cm (reference group). Serum levels of IL-37 among the patients of mycetoma showed no significant difference between males and females, p value = 0.176 <ref type="table" target="#tab_6">(Table 6</ref>). Circulating levels of IL-37 significantly decreased with   <ref type="table" target="#tab_6">(Table 6</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Risk factors for increasing circulating IL-35 and the patients' demographic characteristics and lesion diameters</head><p>The analysis of the risk factors of higher serum levels of IL-35 in mycetoma patients showed no significant association with IL-12, p value = 0.182 <ref type="table">(Table 7)</ref>. Circulating levels of IL-35 among the patients with lesions' diameter � 5 cm and 5-10 cm were significantly decreased by 174.4% and 176.5, respectively; compared to patients with lesion diameter � 10 cm (reference group), p value &lt; 0.001 <ref type="table">(Table 7)</ref>. Serum levels of IL-35 among mycetoma patients showed no significant difference between males and female, p value = 0.575 <ref type="table">(Table 7)</ref>. Circulating levels of IL-35 showed no significant association with the different age groups and different types of antifungal medication given <ref type="table">(Table 7)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Risk factors for circulating IL-37 and the patients' demographic characteristics and disease durations</head><p>The analysis of the risk factors of higher circulatory levels of IL-37 in patients of mycetoma showed a negative significant association with IL-1β, where a unit increment in IL-1β decreases the levels of IL-37 by 35.28 pg/ml, p &lt; 0.001 <ref type="table" target="#tab_7">(Table 8)</ref>. Levels of IL-37 among patients with a disease duration � 1 year had significantly decreased on average by 18.45 pg/ ml compared to patients with a disease duration � 5years (reference group). However, there was no significant difference in levels of IL-37 between patients with infection duration 2-4 years and � 5 years, p value = 0.793 <ref type="table" target="#tab_7">(Table 8</ref>). In addition, serum levels of IL-37 among the mycetoma patients showed no significant difference between males and females, p value = 0.627 <ref type="table" target="#tab_7">(Table 8)</ref>. Furthermore, the circulating levels of IL-37 had significantly decreased with increasing age groups [(19-24 years; p value = 0.022), 25-29 years; p value = 0.030 and (30-39) years; p value = 0.022], <ref type="table" target="#tab_7">(Table 8)</ref>. Interestingly, levels of IL-37 among mycetoma patients showed a statistically significant difference between itraconazole compared to ketoconazole, p &lt; 0.001 <ref type="table" target="#tab_7">(Table 8)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Risk factors for circulating IL-35 among mycetoma patients with different disease</head><p>The analysis of the risk factors of higher levels of IL-35 in patients of mycetoma revealed a negative significant association with IL-12; as a unit increment in IL-12 decreases the levels of IL-35 by 8.99 pg/ml, p value &lt; 0.001 <ref type="table" target="#tab_8">(Table 9</ref>). Levels of IL-35 among the patients with a mycetoma with a disease duration of � 1 year had significantly decreased, p value = 0.002, on average by 41.82 pg/ml compared to patients with a disease duration � 5years (reference group), <ref type="table" target="#tab_8">(Table 9</ref>). However, patients with an infection duration of 2-4 years and � 5 years showed no significant difference in IL-35 levels, p value = 0.391. Furthermore, there was no significant difference (p value = 0.49) in IL-35 levels between male and female mycetoma sufferers <ref type="table" target="#tab_8">(Table 9)</ref>. Additionally, the circulating levels of IL-35 showed no significant association with the different age groups <ref type="table" target="#tab_8">(Table 9)</ref>. Interestingly, mycetoma patients who were treated with itraconazole showed significant increased levels of IL-35 compared to the patients treated with ketoconazole, p value &lt;0.001 ( <ref type="table" target="#tab_8">Table 9</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p>Although mycetoma represents a major health problem in many tropical and subtropical areas, there is no prevention or control measures for this neglected disease <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b22">23]</ref>. In mycetoma endemic areas, most individuals have antibodies against the causative agents, however only few develop disease <ref type="bibr" target="#b3">[4]</ref>. Few researchers believed that patients who develop mycetoma seem to be deficient in their cell-mediated immunity <ref type="bibr" target="#b5">[6]</ref>. Hence, we aimed to investigate the profiles of the pro-inflammatory (IL-1β and IL-12) and the anti-inflammatory immunosuppressive (IL-37 and IL-35) cytokines among mycetoma patients and their association with disease characteristics. As far as we know, this is the first study addressing the relation between immunosuppressive cytokines (IL-37 and IL-35) and mycetoma infection. Our data showed that eumycetoma patients presented higher circulating levels of IL-1β, IL-12, IL-37 and IL-35 compared to controls. In addition, serum levels of IL-1β and IL-12 were significantly decreased with increasing lesions' diameter and disease duration, whereas levels of IL-37 and IL-35 were significantly higher with increasing lesions' diameter and disease duration. These findings indicate that immunosuppressive cytokines like IL-37 and IL-35, which could suppress cellmediated immune responses, may exacerbate the disease progression. Data of the current study clearly showed the serum levels of IL-1β and IL-12 in eumycetoma patients with different lesion size and disease duration were positively correlated with each other, and negatively correlated with IL-35 and IL-37. It has been demonstrated that the first line of innate immune response against mycetoma infection is by phagocytes, from which macrophages represent the major phagocytic cells <ref type="bibr" target="#b49">[50]</ref>. In general, protective immunity to fungal infections <ref type="bibr" target="#b50">[51]</ref> involves activation of TLRs generating inflammatory cytokines through pattern-recognition receptors and pathogen associated molecular patterns <ref type="bibr" target="#b51">[52,</ref><ref type="bibr" target="#b52">53]</ref>. IL-1β and other pro-inflammatory cytokines are produced early in response to fungal infections and promote phagocytosis and other means of innate immune response <ref type="bibr" target="#b53">[54,</ref><ref type="bibr" target="#b54">55]</ref>. Following inflammatory stimuli, several cell types including immune and non-immune cells produce IL-37, as a protective mechanism to prevent runaway inflammation and excessive tissue damage <ref type="bibr" target="#b55">[56]</ref>. IL-37 directly inhibits generation of pro-inflammatory cytokines and down-regulates macrophage cytokine release, and therefore innate immunity <ref type="bibr" target="#b56">[57,</ref><ref type="bibr" target="#b57">58]</ref>. Moreover, IL-37 induces macrophages towards an M2-like phenotype <ref type="bibr" target="#b58">[59]</ref>. M1 macrophages are the most critical effector cells in the innate immune defense system and are characterised by high expression levels of iNOS, subsequent NO production and secretion of pro-inflammatory cytokines, such as IL-1β and IL-12 <ref type="bibr" target="#b59">[60]</ref>. However, M2 macrophages secrete antiinflammatory cytokines, such as IL-10 [61] and express arginase 1, which inhibits NO production, thus rendering these cells ineffective in killing infectious agents including fungal agents <ref type="bibr" target="#b60">[61,</ref><ref type="bibr" target="#b61">62]</ref>. Furthermore, DCs expressing IL-37 secreted higher levels of IL-10 and reduced levels of IL-1β and IL-12. Therefore, the presence of IL-37 in DCs impairs their function in prime T cells and promotes their ability to induce Treg cells that produce IL-10, which is also a potent anti-inflammatory cytokine <ref type="bibr" target="#b29">[30]</ref>. Our results have consistently shown higher circulatory levels of IL-37 in patients of mycetoma which is negatively associated with IL-1β, as a unit increment in IL-1β decreases the levels of IL-37 by 35.28 pg/ml. Based on the aforementioned data, we can speculate that IL-37 could play a role in damping inflammatory response in mycetoma infection which leads to disease progression and this is not in the patient's favor.</p><p>In the current work, the circulating levels of IL-1β and IL-12 in eumycetoma patients with different lesion size and disease duration were negatively correlated with IL-35; whereas serum levels of IL-35 were increased with increasing lesion size and disease duration, and levels of IL-1β and IL-12 simultaneously decreased. This may probably be an attempt to dampen ongoing inflammation. Both IL-1β and IL-12 have a pivotal role in inflammatory and cell-mediated immune responses. Macrophages, Th1 and cytotoxic T-cells (CTLs), which constitute the main component of cell-mediated immunity, play an important role in the protective immunity against mycetoma infection <ref type="bibr" target="#b1">[2]</ref>. As fatal dissemination of N. asteroids infection occurs in nude athymic rats and mice <ref type="bibr" target="#b10">[11,</ref><ref type="bibr" target="#b11">12]</ref>, T cells from previously immunized animals are able to kill N. asteroids in new infections <ref type="bibr" target="#b11">[12,</ref><ref type="bibr" target="#b12">13]</ref>. IL-35 could suppress Th1 and macrophage responses <ref type="bibr" target="#b62">[63]</ref>, whereas deficiency in IL-35 increases macrophage's activation and induces Th1 responses <ref type="bibr" target="#b34">[35,</ref><ref type="bibr" target="#b62">63]</ref>. The increased immunity found in mice lacking IL-35 is associated with a higher activation of macrophages and inflammatory T cells, as well as enhancing function of antigen-presenting cells <ref type="bibr" target="#b34">[35]</ref>. In another infection model, Cao and his co-workers reported higher serum levels of IL-35 in septic patients compared to controls, and IL-35 gradually increased with increased sepsis severity. Moreover, administration of anti-IL-35 antibodies diminished dissemination of the bacteria in septic animals and enhanced local neutrophil recruitment with increasing in inflammatory cytokines and chemokines production <ref type="bibr" target="#b42">[43]</ref>. Furthermore, IL-35 suppressed the proliferation of antigen-specific CTLs and IFN-γ production <ref type="bibr" target="#b63">[64]</ref>. Our data revealed that higher levels of IL-35 in patients with mycetoma is negatively associated with IL-12, where a unit increment in IL-12 decreases the levels of IL-35 by 8.99 pg/ml. This finding indicates that IL-35 may be a risk factor for mycetoma infection and have a negative role in the clinical presentation of the disease.</p><p>Prevalence of mycetoma infection may vary with age. Data from this study showed variation of mycetoma prevalence with age; 74.3% of the patients' age were 19-39 years. This finding is consistent with previous studies which reported that mycetoma mostly affects ages between 20 and 40 years-old, In addition, our data demonstrated that mycetoma infection was predominant in males, as the male to female ratio in patient's group was 4:1. This finding is running parallel with the results of a previous study which demonstrated that in a tertiary facility in Khartoum, Sudan, the male to female ratio is 4:1, whereas at the primary care level in White Nile State, Sudan, the reported male to female ratio was 1.6:1. Another studies reported that male to female ratios in mycetoma infections were in the range of 1.6-6.6:1 <ref type="bibr" target="#b1">[2]</ref>. The predominance of mycetoma in males may be attributed to increased exposure in men who engage in different manual labors including agricultural work. Moreover, influence of sex hormones might have a role in susceptibility to mycetoma infections and disease progression <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b64">65]</ref>.</p><p>Our data showed that about, 50% of the patients have lesion diameter more than 10 cm. This result reflected that most mycetoma patients tend to present late with massive lesions. This finding could be attributed to the nature of mycetoma which is usually painless and slowly progressive. In addition, the lack of health facilities in endemic areas, the low socio-economic status of the affected patients and their poor health education <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b65">66]</ref> are amongst the reasons why the current treatment of mycetoma is suboptimal, characterised by low cure rates and frequent recurrence often leading to amputation <ref type="bibr" target="#b66">[67,</ref><ref type="bibr" target="#b67">68]</ref>. However, clinical experience shows that early and small mycetoma lesions are associated with good outcome and prevent severe complications of the disease.</p><p>One of the remarkable findings of the current study is the significant increase of IL-37 and IL-35 levels with itraconazole treatment compared to the ketoconazole. A previous study by Friccius and colleagues suggested that the dose of 10 μg/ml itraconazole leads to strong inhibition of the cytokines IL-2, IL-4, IL-9 and IFN-γ and slight inhibition of TNF-α cytokine production in PBMC after 6 and 24 hours of incubation. These results demonstrate that IL-35 and IL-37 can be one of the underline factors associated with inhibition of the cytokines related to Itraconazole <ref type="bibr" target="#b68">[69]</ref>.</p><p>In conclusion, our study revealed that the levels of IL-37 and IL-35 were consistently positively correlated with different diameters of mycetoma lesions as well as its duration. However, the levels of IL-1β and IL-12 were consistently negatively correlated with different diameters of lesions and the duration of mycetoma infection. The analysis of the risk factors of higher circulatory levels of IL-37 in patients of mycetoma showed a negative significant association with IL-1β cytokine, where a unit increment in IL-1β will decrease the levels of IL-37 by 35.28 pg/ ml. Levels of IL-37 among the patients with a mycetoma infection duration � 1 year had significantly decreased on average by 18.45 pg/ml compared to patients with a mycetoma infection duration � 5years (reference group). Furthermore, the risk factors of higher levels of IL-35 in patients of mycetoma revealed a negative significant association with IL-12, as a unit increment in IL-12 decreases the levels of IL-35 decrease by 8.99 pg/ml, p &lt; 0.001. Levels of IL-35 among the patients with a mycetoma infection duration � 1 year had significantly decreased (p value = 0.002) on average by 41.82 pg/ml compared to patients with a mycetoma infection duration � 5years (reference group). More investigations are needed to explore the mechanism by which IL-35 and IL-37 contribute in the mycetoma infection outcomes. This will help in understanding the role of these cytokines IL-35 and IL-37 in the pathogenesis of mycetoma, and may exploit it as a potential therapeutic target to prevent mycetoma diseases recurrence.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supporting information</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>S1 Checklist. STROBE checklist. (DOC)</head></div><figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0" validated="false"><head></head><label></label><figDesc>Table 1). In this study, a total of 40 subjects [23 patients (32.9%) and 17 (24.3%) healthy controls] were domestic workers, 40 individuals [17 (24.3%) patients and 23 (32.9%) healthy controls] were students and 24 individuals [12 (17.1%) patients and 12 (17.1%) healthy controls] were farmers. Due to the prolonged illness and disability, 12 (17.1%) patients had lost their jobs while only 5 (7.1%) healthy controls were unemployed. A total of 6 individuals [5 (7.1%) patients and 1(1.4%) healthy controls] of the patients were housewives. A total of 13 individuals [1(1.4%) patients and 12 (17.1%) healthy controls] were employers (Table 1).</figDesc><table>22 
(31.4%)] was 19-24 years, 17 (22.9%) in the age group (25-29) years, and nine (12.9%) were 40 
years old or more (</table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1" validated="false"><head>Table 1 .</head><label>1</label><figDesc>Demographic characteristics of the study populations.</figDesc><table>Controls 
n = 70 (%) 

Mycetoma Patients n = 70 (%) 

</table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2" validated="true"><head>Table 2 .</head><label>2</label><figDesc>Correlations between the serum levels of (IL-1β, IL-37, IL-12 and IL-35) by the lesion diameter and the control group.</figDesc><table>Lesion diameter 
Cytokine Levels pg/ml 
IL-1β pg/ml 
IL-37 pg/ml 
IL-12 pg/ml 
IL-35 pg/ml 

Controls (no lesion) 
IL-1β 
1 

IL-37 
0.115 
1 

IL-12 
0.137 
-0.023 
1 

IL-35 
-0.125 
0.037 
0.065 
1 

�5 cm 
IL-1β 
1 

IL-37 
-0.992 

�� 

1 

IL-12 
0.987 

�� 

-0.996 

�� 

1 

IL-35 
-0.924 

�� 

0.945 

�� 

-0.949 

�� 

1 

5-10 cm 
IL-1β 
1 

IL-37 
-0.991 

�� 

1 

IL-12 
0.991 

�� 

-0.995 

�� 

1 

IL-35 
-0.983 

�� 

0.989 

�� 

-0.983 

�� 

1 

�10 cm 
IL-1β 
1 

IL-37 
-0.998 

�� 

1 

IL-12 
0.969 

�� 

-0.971 

�� 

1 

IL-35 
-0.994 

�� 

0.995 

�� 

-0.964 

�� 

1 

�� Spearman's rho Correlation is significant at the 0.01 level (2-tailed). 

https://doi.org/10.1371/journal.pntd.0007098.t002 

</table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3" validated="true"><head>Table 3 .</head><label>3</label><figDesc>Correlations between the serum levels of (IL-1β, IL-37, IL-12 and IL-35) by the duration of mycetoma infection and the control group.</figDesc><table>Duration 
Cytokine Levels pg/ml 
IL-1β pg/ml 
IL-37 pg/ml 
IL-12 pg/ml 
IL-35 pg/ml 

Control 
IL-1β 
1 

IL-37 
0.115 
1 

IL-12 
0.137 
-0.023 
1 

IL-35 
-0.125 
0.037 
0.065 
1 

�1 Years 
IL-1β 
1 

IL-37 
-0.997 

�� 

1 

IL-12 
0.997 

�� 

-0.999 

�� 

1 

IL-35 
-0.996 

�� 

0.997 

�� 

-0.995 

�� 

1 

2-4 years 
IL-1β 
1 

IL-37 
-0.999 

�� 

1 

IL-12 
0.996 

�� 

-0.997 

�� 

1 

IL-35 
-0.997 

�� 

0.997 

�� 

-0.994 

�� 

1 

�5 years 
IL-1β 
1 

IL-37 
-0.999 

�� 

1 

IL-12 
0.986 

�� 

-0.986 

�� 

1 

IL-35 
-0.998 

�� 

0.997 

�� 

-0.986 

�� 

1 

�� Spearman's rho Correlation is significant at the 0.01 level (2-tailed). </table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4" validated="true"><head>Table 4 .</head><label>4</label><figDesc>Analysis of the serum cytokine levels of (IL-1β, IL-37, IL-12 and IL-35) within the different lesion diameter among mycetoma patient and control groups.</figDesc><table>Cytokines Levels pg/ml 
Lesion diameter 
Mean± SD 
Median 
(Q1-Q3) 
P-value 

� 

IL-1β 
Control 
1.16± 3.15 
0.11 
0.3-0.6 
&lt;0.001 

�5 cm 
3.39± 1.07 
2.45 
2.5-4.5 

5-10 cm 
2.32± 0.05 
2.3 
2.3-2.3 

�10 cm 
2.08± 0.11 
1.97 
2.1-2.1 

IL-37 
Control 
22.06± 2.39 
20 
22-24 
&lt;0.001 

�5 cm 
107.92± 5.96 
104 
108-112 

5-10 cm 
141.45± 12.96 
129 
143-152 

�10 cm 
193.20± 15.01 
184.17 
189-199 

IL-12 
Control 
2.46± 1.02 
1.96 
2.4-2.5 
&lt;0.001 

�5 cm 
25.22± 3.34 
23.2 
25-28 

5-10 cm 
14.45± 3.32 
12.4 
12.9-18.2 

�10 cm 
9.65± 0.36 
9.49 
9.5-9.8 

IL-35 
Control 
15.97± 2.6 
14.6 
16.4-18.2 
&lt;0.001 

�5 cm 
255.15± 1.72 
253 
255-257 

5-10 cm 
263.23± 3.26 
261 
262-267 

�10 cm 
449.71± 22.2 
430 
447-456 

� P values are derived from non-parametric method; Kruskal Wallis test. 

https://doi.org/10.1371/journal.pntd.0007098.t004 

</table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5" validated="true"><head>Table 5 .</head><label>5</label><figDesc>Analysis of the serum cytokine levels of (IL-1β, IL-37, IL-12 and IL-35) among mycetoma patient stratified by different duration of mycetoma infection compared to controls group.</figDesc><table>Cytokines 
pg/ml 

Duration 
Mean± SD 
Median 
(Q1-Q3) 
P-value 

� 

IL-1β 
Control 
1.2± 3.1 
0.4 
(0.1-0.6) 
0.017 

�1 year 
2.3± 0.1 
2.3 
(2.2-2.4) 

2-4 years 
2.6± 0.9 
2.2 
(2.1-2.4) 

�5 years 
2.3± 0.5 
2.2 
(2.0-2.3) 

IL-37 
Control 
22.1± 2.4 
22.0 
(20-24) 
&lt;0.001 

�1 year 
146.7± 28.4 
145.0 
(122-160) 

2-4 years 
160.9± 41.3 
178.0 
(127-190) 

�5 years 
175.7± 33.9 
185.2 
(156-194) 

IL-12 
Control 
2.5± 1.0 
2.4 
(2.0-2.5) 
&lt;0.001 

�1 year 
14.9± 5.0 
12.5 
(10.5-19.5) 

2-4 years 
15.0± 7.5 
10.2 
(9.5-19.4) 

�5 years 
12.1± 5.4 
9.8 
(9.5-12.1) 

IL-35 
Control 
16.0± 2.6 
16.4 
(14.6-18.2) 
&lt;0.001 

�1 year 
301.9± 75.9 
262.5 
(260-271) 

2-4 years 
363.8± 101.5 
423.5 
(260-447) 

�5 years 
397.6± 88.1 
436.0 
(267-450) 

� P values are derived from non-parametric method; Kruskal Wallis test. 

https://doi.org/10.1371/journal.pntd.0007098.t005 

</table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6" validated="false"><head>Table 6 .</head><label>6</label><figDesc>Risk factors for circulating cytokines IL-37 pg/ml in mycetoma patients with different lesion diameters.https://doi.org/10.1371/journal.pntd.0007098.t006 Table 7. Risk factors for circulating cytokines IL-35 pg/ml in mycetoma patients with different lesion diameters.</figDesc><table>variable 
Category 
B 

 ‡ 

95% Confidence Interval 
p-value 

(Lower to Upper) 

Intercept 
228.4 
(208.6 to 248.1) 
&lt;0.001 

IL-1β 
-9.1 
(-15.7 to -2.5) 
0.008 

Lesion diameter 
�5 cm 
-75.4 
(-88.4 to -62.3) 
&lt;0.001 

5-10 cm 
-52.6 
(-64.3 to -40.8) 
&lt;0.002 

�10 cm 
0 

Gender 
Female 
-5.3 
(-13.1 to 2.5) 
0.176 

Male 
0 

Age groups years 
12-18 
-11.7 
(-23.2 to -0.2) 
0.047 

19-24 
-13.3 
(-23.2 to -3.3) 
0.010 

25-29 
-9.5 
(-20.0 to 1.1) 
0.079 

30-39 
-11.8 
(-22.3 to -1.2) 
0.029 

�40 
0 

Medication 
Itraconazole 
200 mg/day 

-5.7 
(-16.4 to 5) 
0.293 

Ketoconazole 
400 mg/day 

0 

 ‡ B (95%CI) adjusted with lesion diameter, gender, age groups and medical treatments. 

Parameter 
B 

 ‡ 

95% Confidence Interval 
(Lower to Upper) 

P-value 

Intercept 
460.0 
(437.5 to 482.4) 
&lt;0.001 

IL-12 
-1.2 
(-2.9 to 0.6) 
0.182 

Lesion diameter 
�5 cm 
-174.4 
(-205.2 to -143.5) 
&lt;0.001 

5-10 cm 
-176.5 
(-194.8 to -158.1) 
&lt;0.001 

�10 cm 
0.0 

Gender 
Female 
-2.9 
(-13.4 to 7.5) 
0.575 

Male 
0.0 

Age groups years 
12-18 
5.6 
(-9.6 to 20.7) 
0.464 

19-24 
-1.8 
(-14.7 to 11.2) 
0.786 

25-29 
-2.5 
(-16.3 to 11.4) 
0.722 

30-39 
-7.9 
(-21.8 to 6.0) 
0.258 

�40 
0.0 

Medication 
Itraconazole 200 mg/day 
2.9 
(-11.4 to 17.3) 
0.683 

Ketoconazole 400 mg/day 
0.0 

 ‡ B (95%CI) adjusted with lesion diameter, gender, age groups and medical treatments. </table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7" validated="false"><head>Table 8 .</head><label>8</label><figDesc>Risk factors for circulating cytokines IL-37 pg/ml among mycetoma patients with different duration of mycetoma infection.</figDesc><table>Parameter 
B 

 ‡ 

95% Confidence Interval 
P-value 

(Lower to Upper) 

Intercept 
436.50 
394.36 to 478.64 
&lt;0.001 

IL-12 
-8.99 
-10.73 to -7.25 
&lt;0.001 

Duration of mycetoma infection 
�1 year 
-41.82 
-67.31 to -16.32 
0.002 

2-4 years 
-10.64 
-35.28 to 14.01 
0.391 

�5 years 
0 

Gender 
Female 
-8.47 
-32.85 to 15.90 
0.49 

Male 
0 

Age groups years 
12-18 
9.23 
-29.02 to 47.48 
0.631 

19-24 
8.00 
-24.05 to 40.06 
0.619 

25-29 
-2.19 
-36.43 to 32.05 
0.899 

30-39 
-30.58 
-66.01 to 4.84 
0.089 

�40 
0 

Medication 
Itraconazole 
200 mg/day 

101.17 
78.40 to 123.95 
&lt;0.001 

Ketoconazole 
400 mg/day 

0 

https://doi.org/10.1371/journal.pntd.0007098.t008 

Interleukins role in mycetoma 

</table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_8" validated="true"><head>Table 9 .</head><label>9</label><figDesc>Risk factors for circulating cytokines IL-35 pg/ml among mycetoma patients with different duration of mycetoma infection.</figDesc><table>Parameter 
B 

 ‡ 

95% Confidence Interval 
P-value 

(Lower to Upper) 

Intercept 
436.50 
394.36 to 478.64 
&lt;0.001 

IL-12 
-8.99 
-10.73 to -7.25 
&lt;0.001 

Duration of mycetoma infection 
�1 year 
-41.82 
-67.31 to -16.32 
0.002 

2-4 years 
-10.64 
-35.28 to 14.01 
0.391 

�5 years 
0 

Gender 
Female 
-8.47 
-32.85 to 15.90 
0.49 

Male 
0 

Age groups years 
12-18 
9.23 
-29.02 to 47.48 
0.631 

19-24 
8.00 
-24.05 to 40.06 
0.619 

25-29 
-2.19 
-36.43 to 32.05 
0.899 

30-39 
-30.58 
-66.01 to 4.84 
0.089 

�40 
0 

Medication 
Itraconazole 
200 mg/day 

101.17 
78.40 to 123.95 
&lt;0.001 

Ketoconazole 
400 mg/day 

0 

 ‡ B (95%CI) adjusted with Duration of mycetoma infection, gender, age groups and medical treatments. </table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007098 April 4, 2019</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p>The authors are grateful to the patients, controls and their families and the staff at the Mycetoma Research Centre at Soba University Hospital, University of Khartoum-Sudan, for their continued collaboration and generous hospitality during a decade of samples collection. The authors are thankful to Dr. Hamza A., Dundee University, UK for improving the English language and proof reading the Manuscript.</p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Mycetoma in the Sudan: an update from the mycetoma research centre</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Fahal</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">S</forename><surname>Mahgoub</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ame</forename><surname>Hassan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">E</forename><surname>Abdel-Rahman</surname></persName>
		</author>
		<idno type="doi">10.1371/journal.pntd.0003679PMID</idno>
		<ptr target="https://doi.org/10.1371/journal.pntd.0003679PMID" />
	</analytic>
	<monogr>
		<title level="j">PLoS Negl Trop Dis</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">25816316</biblScope>
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title level="m" type="main">Mycetoma: a unique neglected tropical disease. The Lancet Infectious Diseases</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">E</forename><surname>Zijlstra</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">W</forename><surname>Van De Sande</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>Welsh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Goodfellow</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">H</forename><surname>Fahal</surname></persName>
		</author>
		<idno>1016/ S1473-3099(15)00359-X PMID: 26738840</idno>
		<ptr target="https://doi.org/10" />
		<imprint>
			<date type="published" when="2016" />
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="100" to="112" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">H</forename><surname>Fahal</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">A</forename><surname>Hassan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Surg</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="page">1467883</biblScope>
			<date type="published" when="1992" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Host defenses in subcutaneous mycoses</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Vera-Cabrera</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">C</forename><surname>Salinas-Carmona</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Waksman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Messeguer-Pé Rez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Ocampo-Candiani</surname></persName>
		</author>
		<idno type="doi">10.1016/j.clindermatol.2011.09.008PMID</idno>
		<ptr target="https://doi.org/10.1016/j.clindermatol.2011.09.008PMID" />
	</analytic>
	<monogr>
		<title level="j">Clinics in dermatology</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page">22682185</biblScope>
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">The immunopathology of actinomycetoma lesions caused by Streptomyces somaliensis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>El Hassan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">H</forename><surname>Fahal</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Ahmed</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Ismail</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Veress</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transactions of the Royal Society of Tropical Medicine and Hygiene</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page">11280076</biblScope>
			<date type="published" when="2001" />
			<publisher>PMID</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title level="m" type="main">Bulletin de la Societe de Pathologie Exotique et de ses Filiales</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Mahgoub</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Gumaa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">El</forename><surname>Hassan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename></persName>
		</author>
		<imprint>
			<date type="published" when="1976" />
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="48" to="54" />
		</imprint>
	</monogr>
	<note>Immunological status of mycetoma patients</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">The association of HLA-DRB1 and HLA-DQB1 alleles and the occurrence of eumycetoma in Sudanese patients</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Al</forename><surname>Dawi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">F</forename><surname>Mustafa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">I</forename><surname>Fahal</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">H</forename><surname>Hassan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ame</forename><surname>Bakhiet</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Khartoum Medical Journal</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<monogr>
		<title level="m" type="main">Retnla down-regulation and IL-13-rich environment correlate with inflammation severity in experimental actinomycetoma by Nocardia brasiliensis. Pathogens and disease</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Meester</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">G</forename><surname>Rosas-Taraco</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">C</forename><surname>Salinas-Carmona</surname></persName>
		</author>
		<idno type="doi">10.1111/2049-632X.12036PMID</idno>
		<ptr target="https://doi.org/10.1111/2049-632X.12036PMID" />
		<imprint>
			<date type="published" when="2013" />
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page">23620185</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Association of eumycetoma and schistosomiasis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">J</forename><surname>Van Hellemond</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">G</forename><surname>Vonk</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>De Vogel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Koelewijn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Vaessen</surname></persName>
		</author>
		<idno type="doi">10.1371/journal.pntd.0002241PMID</idno>
		<ptr target="https://doi.org/10.1371/journal.pntd.0002241PMID" />
	</analytic>
	<monogr>
		<title level="j">PLoS Negl Trop Dis</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">23717704</biblScope>
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">TLR4 recognizes Pseudallescheria boydii conidia and purified rhamnomannans</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">T</forename><surname>Figueiredo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">L</forename><surname>Fernandez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><forename type="middle">F</forename><surname>Dutra</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Gonzá Lez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">C</forename><surname>Lopes</surname></persName>
		</author>
		<idno type="doi">10.1074/jbc.M110.181255PMID</idno>
		<ptr target="https://doi.org/10.1074/jbc.M110.181255PMID" />
	</analytic>
	<monogr>
		<title level="j">Journal of Biological Chemistry</title>
		<imprint>
			<biblScope unit="volume">285</biblScope>
			<biblScope unit="page">20959459</biblScope>
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Role of passive humoral immunity in experimental mycetoma by Nocardia brasiliensis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Salinas-Carmona</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Torres-Ló Pez E</forename><surname>Mc</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annals of the New York Academy of Sciences</title>
		<imprint>
			<biblScope unit="volume">797</biblScope>
			<biblScope unit="page">8993374</biblScope>
			<date type="published" when="1996" />
			<publisher>PMID</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Actinomycetoma and advances in its treatment</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>Welsh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Vera-Cabrera</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Welsh</forename><forename type="middle">E</forename><surname>Salinas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">C</forename></persName>
		</author>
		<idno type="doi">10.1016/j.clindermatol.2011.06.027PMID</idno>
		<ptr target="https://doi.org/10.1016/j.clindermatol.2011.06.027PMID" />
	</analytic>
	<monogr>
		<title level="j">Clinics in dermatology</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page">22682184</biblScope>
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Immunologically specific direct T lymphocyte-mediated killing of Nocardia asteroides</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Deem</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Doughty</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Beaman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Journal of Immunology</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="page">6339627</biblScope>
			<date type="published" when="1983" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Nocardia brasiliensis cell wall lipids modulate macrophage and dendritic responses that favor development of experimental actinomycetoma in BALB/c mice</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">H</forename><surname>Trevino-Villarreal</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Vera-Cabrera</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">L</forename><surname>Valero-Guillé N</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">C</forename><surname>Salinas-Carmona</surname></persName>
		</author>
		<idno type="doi">10.1128/IAI.00446-12PMID</idno>
		<ptr target="https://doi.org/10.1128/IAI.00446-12PMID" />
	</analytic>
	<monogr>
		<title level="j">Infection and immunity</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="page">22851755</biblScope>
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Serum IL-1beta levels in health and disease: a population-based study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Di</forename><surname>Iorio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Ferrucci</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Sparvieri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Cherubini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Volpato</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cytokine</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page">12890453</biblScope>
			<date type="published" when="2003" />
			<publisher>PMID</publisher>
		</imprint>
	</monogr>
	<note>The InCHIANTI study&apos;</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Cytokines and heart failure</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">J</forename><surname>Paulus</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Heart Fail Monit</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page">12634874</biblScope>
			<date type="published" when="2000" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Th-1, Th-2 Cytokines Profile among Madurella mycetomatis Eumycetoma Patients</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Nasr</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Abushouk</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Hamza</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Siddig</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">H</forename><surname>Fahal</surname></persName>
		</author>
		<idno type="doi">10.1371/journal.pntd.0004862PMID</idno>
		<ptr target="https://doi.org/10.1371/journal.pntd.0004862PMID" />
	</analytic>
	<monogr>
		<title level="j">PLoS Negl Trop Dis</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">27434108</biblScope>
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Caspase-8 modulates dectin-1 and complement receptor 3-driven IL-1beta production in response to beta-glucans and the fungal pathogen, Candida albicans</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Ganesan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><forename type="middle">A</forename><surname>Rathinam</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Bossaller</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Army</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">J</forename><surname>Kaiser</surname></persName>
		</author>
		<idno type="doi">10.4049/jimmunol.1400276PMID</idno>
		<ptr target="https://doi.org/10.4049/jimmunol.1400276PMID" />
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">193</biblScope>
			<biblScope unit="page">25063877</biblScope>
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">IL-37 is a fundamental inhibitor of innate immunity</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">F</forename><surname>Nold</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">A</forename><surname>Nold-Petry</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">A</forename><surname>Zepp</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">E</forename><surname>Palmer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Bufler</surname></persName>
		</author>
		<idno type="doi">10.1038/ni.1944PMID</idno>
		<ptr target="https://doi.org/10.1038/ni.1944PMID" />
	</analytic>
	<monogr>
		<title level="j">Nat Immunol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">20935647</biblScope>
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Association of IL-37 gene polymorphisms with susceptibility to tuberculosis in Saudi population</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Allam</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">A</forename><surname>Mohamed</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">A</forename><surname>Alswat</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">H</forename><surname>Abbadi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Nassif</surname></persName>
		</author>
		<idno type="doi">10.1111/1348-0421.12444</idno>
		<ptr target="https://doi.org/10.1111/1348-0421.12444" />
	</analytic>
	<monogr>
		<title level="j">Microbiology and Immunology</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="778" to="786" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">IL-37 inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: its correlation with disease activity</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Ye</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ji</forename><forename type="middle">L</forename><surname>Wen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename></persName>
		</author>
		<idno type="doi">10.1186/1479-5876-12-69PMID</idno>
		<ptr target="https://doi.org/10.1186/1479-5876-12-69PMID" />
	</analytic>
	<monogr>
		<title level="j">J Transl Med</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">24629023</biblScope>
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">The possible role of the novel cytokines il-35 and il-37 in inflammatory bowel disease</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><surname>Zuo</surname></persName>
		</author>
		<idno type="doi">10.1155/2014/136329PMID</idno>
		<ptr target="https://doi.org/10.1155/2014/136329PMID" />
	</analytic>
	<monogr>
		<title level="j">Mediators Inflamm</title>
		<imprint>
			<biblScope unit="page">25214710</biblScope>
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Downregulated interleukin 37 expression associated with aggravation of intervertebral disc degeneration</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><forename type="middle">Y</forename><surname>Wan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">F</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">L</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Clin Exp Pathol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">24551286</biblScope>
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Increased expression of IL-37 in patients with Graves&apos; disease and its contribution to suppression of proinflammatory cytokines production in peripheral blood mononuclear cells</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<idno type="doi">10.1371/journal.pone.0107183PMID</idno>
		<ptr target="https://doi.org/10.1371/journal.pone.0107183PMID" />
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">25226272</biblScope>
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">IL-37: a new anti-inflammatory cytokine of the IL-1 family</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Boraschi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Lucchesi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Hainzl</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Leitner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Maier</surname></persName>
		</author>
		<idno type="doi">10.1684/ecn.2011.0288PMID</idno>
		<ptr target="https://doi.org/10.1684/ecn.2011.0288PMID" />
	</analytic>
	<monogr>
		<title level="j">Eur Cytokine Netw</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page">22047735</biblScope>
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Banchereau</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Pascual</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>O&amp;apos;garra</surname></persName>
		</author>
		<idno type="doi">10.1038/ni.2406PMID</idno>
		<ptr target="https://doi.org/10.1038/ni.2406PMID" />
	</analytic>
	<monogr>
		<title level="j">Nat Immunol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">22990890</biblScope>
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Interleukin 37 expression protects mice from colitis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">N</forename><surname>Mcnamee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">C</forename><surname>Masterson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Jedlicka</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Mcmanus</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Grenz</surname></persName>
		</author>
		<idno type="doi">10.1073/pnas.1111982108PMID</idno>
		<ptr target="https://doi.org/10.1073/pnas.1111982108PMID" />
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="page">21873195</biblScope>
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Protective host defense against disseminated candidiasis is impaired in mice expressing human interleukin-37</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><forename type="middle">L</forename><surname>Van De Veerdonk</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">S</forename><surname>Gresnigt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Oosting</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">W</forename><surname>Van Der Meer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">A</forename><surname>Joosten</surname></persName>
		</author>
		<idno type="doi">10.3389/fmicb.2014.00762PMID</idno>
		<ptr target="https://doi.org/10.3389/fmicb.2014.00762PMID" />
	</analytic>
	<monogr>
		<title level="j">Frontiers in microbiology</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">25620965</biblScope>
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">IL-37 inhibits inflammasome activation and disease severity in murine aspergillosis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Moretti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Bozza</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Oikonomou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Renga</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Casagrande</surname></persName>
		</author>
		<idno type="doi">10.1371/journal.ppat.1004462PMID</idno>
		<ptr target="https://doi.org/10.1371/journal.ppat.1004462PMID" />
	</analytic>
	<monogr>
		<title level="j">PLoS Pathog</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">25375146</biblScope>
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">A</forename><surname>Nold-Petry</surname></persName>
		</author>
		<idno type="doi">10.1073/pnas.1416714111PMID</idno>
		<ptr target="https://doi.org/10.1073/pnas.1416714111PMID" />
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page">25294929</biblScope>
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">IL-12 and related cytokines: function and regulatory implications in Candida albicans infection</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">B</forename><surname>Ashman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Vijayan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">A</forename><surname>Wells</surname></persName>
		</author>
		<idno type="doi">10.1155/2011/686597PMID</idno>
		<ptr target="https://doi.org/10.1155/2011/686597PMID" />
	</analytic>
	<monogr>
		<title level="j">Clin Dev Immunol</title>
		<imprint>
			<biblScope unit="page">21052539</biblScope>
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">From IL-10 to IL-12: how pathogens and their products stimulate APCs to induce T(H)1 development</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>O&amp;apos;garra</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">M</forename><surname>Murphy</surname></persName>
		</author>
		<idno type="doi">10.1038/ni0909-929PMID</idno>
		<ptr target="https://doi.org/10.1038/ni0909-929PMID" />
	</analytic>
	<monogr>
		<title level="j">Nat Immunol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">19692989</biblScope>
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">The inhibitory cytokine IL-35 contributes to regulatory T-cell function</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">W</forename><surname>Collison</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">J</forename><surname>Workman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">T</forename><surname>Kuo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Boyd</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<idno type="doi">10.1038/nature06306PMID</idno>
		<ptr target="https://doi.org/10.1038/nature06306PMID" />
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">450</biblScope>
			<biblScope unit="page">18033300</biblScope>
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">IL-12 family cytokines: immunological playmakers</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">A</forename><surname>Vignali</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><forename type="middle">K</forename><surname>Kuchroo</surname></persName>
		</author>
		<idno type="doi">10.1038/ni.2366PMID</idno>
		<ptr target="https://doi.org/10.1038/ni.2366PMID" />
	</analytic>
	<monogr>
		<title level="j">Nature immunology</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">22814351</biblScope>
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Roch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Lampropoulou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">A</forename><surname>O&amp;apos;connor</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">U</forename><surname>Stervbo</surname></persName>
		</author>
		<idno type="doi">10.1038/nature12979PMID</idno>
		<ptr target="https://doi.org/10.1038/nature12979PMID" />
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">507</biblScope>
			<biblScope unit="page">24572363</biblScope>
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Human tolerogenic dendritic cells produce IL-35 in the absence of other IL-12 family members</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">O</forename><surname>Dixon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">W</forename><surname>Der Kooij</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">A</forename><surname>Vignali</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Kooten</surname></persName>
		</author>
		<idno type="doi">10.1002/eji.201445217</idno>
		<ptr target="https://doi.org/10.1002/eji.201445217" />
	</analytic>
	<monogr>
		<title level="j">European journal of immunology</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="1736" to="1747" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">IL-35 and autoimmunity: a comprehensive perspective</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">S</forename><surname>Leung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Bowlus</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">E</forename><surname>Gershwin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clinical reviews in allergy &amp; immunology</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="327" to="332" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Epstein-Barr virus-induced gene 3 negatively regulates neuroinflammation and T cell activation following coronavirus-induced encephalomyelitis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Tirotta</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Duncker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Oak</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Klaus</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">R</forename><surname>Tsukamoto</surname></persName>
		</author>
		<idno type="doi">10.1016/j.jneuroim.2012.10.005PMID</idno>
		<ptr target="https://doi.org/10.1016/j.jneuroim.2012.10.005PMID" />
	</analytic>
	<monogr>
		<title level="j">Journal of neuroimmunology</title>
		<imprint>
			<biblScope unit="volume">254</biblScope>
			<biblScope unit="page">23102608</biblScope>
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Kochetkova</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Golden</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Holderness</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Callis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">W</forename><surname>Pascual</surname></persName>
		</author>
		<idno type="doi">10.4049/jimmunol.0902739PMID</idno>
		<ptr target="https://doi.org/10.4049/jimmunol.0902739PMID" />
	</analytic>
	<monogr>
		<title level="j">The Journal of Immunology</title>
		<imprint>
			<biblScope unit="volume">184</biblScope>
			<biblScope unit="page">20483737</biblScope>
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Niedbala</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wei</forename><surname>Xq</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">J</forename><surname>Hueber</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">P</forename><surname>Leung</surname></persName>
		</author>
		<idno type="doi">10.1002/eji.200737810PMID</idno>
		<ptr target="https://doi.org/10.1002/eji.200737810PMID" />
	</analytic>
	<monogr>
		<title level="j">European journal of immunology</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page">17874423</biblScope>
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Airway inflammation and IgE production induced by dust mite allergen-specific memory/effector Th2 cell line can be effectively attenuated by IL-35</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C-H</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ex-L</forename><surname>Loo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I-C</forename><surname>Kuo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">H</forename><surname>Soh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dl-M</forename><surname>Goh</surname></persName>
		</author>
		<idno type="doi">10.4049/jimmunol.1100259PMID</idno>
		<ptr target="https://doi.org/10.4049/jimmunol.1100259PMID" />
	</analytic>
	<monogr>
		<title level="j">The Journal of Immunology</title>
		<imprint>
			<biblScope unit="volume">187</biblScope>
			<biblScope unit="page">21613618</biblScope>
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">IL-35 production by inducible costimulator (ICOS)-positive regulatory T cells reverses established IL-17-dependent allergic airways disease</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">S</forename><surname>Whitehead</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">H</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Nakano</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">H</forename><surname>Burch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Nakano</surname></persName>
		</author>
		<idno type="doi">10.1016/j.jaci.2011.08.009PMID</idno>
		<ptr target="https://doi.org/10.1016/j.jaci.2011.08.009PMID" />
	</analytic>
	<monogr>
		<title level="j">Journal of Allergy and Clinical Immunology</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="page">21906794</biblScope>
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">IL-35 is elevated in clinical and experimental sepsis and mediates inflammation</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><surname>Tao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Xiang</surname></persName>
		</author>
		<idno type="doi">10.1016/j.clim.2015.08.016PMID</idno>
		<ptr target="https://doi.org/10.1016/j.clim.2015.08.016PMID" />
	</analytic>
	<monogr>
		<title level="j">Clinical Immunology</title>
		<imprint>
			<biblScope unit="volume">161</biblScope>
			<biblScope unit="page">26342538</biblScope>
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Elevated serum IL-35 and increased expression of IL-35-p35 or-EBI3 in CD4+ CD25+ T cells in patients with active tuberculosis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Kong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G-B</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J-A</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X-X</forename><surname>Fu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W-Y</forename><surname>Xiang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">American journal of translational research</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">27158354</biblScope>
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Mycetoma laboratory diagnosis: Review article</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">A</forename><surname>Ahmed</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Van De Sande</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">H</forename><surname>Fahal</surname></persName>
		</author>
		<idno type="doi">10.1371/journal.pntd.0005638PMID</idno>
		<ptr target="https://doi.org/10.1371/journal.pntd.0005638PMID" />
	</analytic>
	<monogr>
		<title level="j">PLoS Negl Trop Dis</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">28837657</biblScope>
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Use of filter paper for the collection and analysis of human whole blood specimens</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">V</forename><surname>Mei</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">R</forename><surname>Alexander</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Adam</forename><surname>Bw</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">H</forename><surname>Hannon</surname></persName>
		</author>
		<idno type="doi">10.1093/jn/131.5.1631SPMID</idno>
		<ptr target="https://doi.org/10.1093/jn/131.5.1631SPMID" />
	</analytic>
	<monogr>
		<title level="j">J Nutr</title>
		<imprint>
			<biblScope unit="volume">131</biblScope>
			<biblScope unit="page">11340130</biblScope>
			<date type="published" when="2001" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Comparison of available methods to elute serum from dried blood spot samples for measles serology</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Mercader</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Featherstone</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">J</forename><surname>Bellini</surname></persName>
		</author>
		<idno type="doi">10.1016/j.jviromet.2006.06.018PMID</idno>
		<ptr target="https://doi.org/10.1016/j.jviromet.2006.06.018PMID" />
	</analytic>
	<monogr>
		<title level="j">J Virol Methods</title>
		<imprint>
			<biblScope unit="volume">137</biblScope>
			<biblScope unit="page">16860401</biblScope>
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">The use of the dried blood spot sample in epidemiological studies</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">P</forename><surname>Parker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">D</forename><surname>Cubitt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Pathol</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page">10655983</biblScope>
			<date type="published" when="1999" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Helsinki Declaration revisited over concerns about human subjects</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Sibbald</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cmaj</title>
		<imprint>
			<biblScope unit="volume">169</biblScope>
			<biblScope unit="page">14609989</biblScope>
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Differential activity of innate defense antimicrobial peptides against Nocardia species</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Rieg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Meier</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Fä Hnrich</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Huth</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Wagner</surname></persName>
		</author>
		<idno type="doi">10.1186/1471-2180-10-61PMID</idno>
		<ptr target="https://doi.org/10.1186/1471-2180-10-61PMID" />
	</analytic>
	<monogr>
		<title level="j">BMC Microbiology</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">61</biblScope>
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<monogr>
		<title level="m" type="main">Immunity to fungi. Current opinion in immunology</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Leibundgut-Landmann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Wü Thrich M</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">M</forename><surname>Hohl</surname></persName>
		</author>
		<idno type="doi">10.1016/j.coi.2012.04.007PMID</idno>
		<ptr target="https://doi.org/10.1016/j.coi.2012.04.007PMID" />
		<imprint>
			<date type="published" when="2012" />
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page">22613091</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">MyD88-deficient Hydra reveal an ancient function of TLR signaling in sensing bacterial colonizers</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Franzenburg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Fraune</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Künzel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">F</forename><surname>Baines</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Domazet-Lošo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proceedings of the National Academy of Sciences</title>
		<imprint>
			<biblScope unit="volume">109</biblScope>
			<biblScope unit="page" from="19374" to="19379" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Role of pathogen-associated molecular patterns (PAMPS) in immune responses to fungal infections</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Taghavi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Khosravi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Mortaz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Nikaein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">S</forename><surname>Athari</surname></persName>
		</author>
		<idno type="doi">10.1016/j.ejphar.2016.11.013PMID</idno>
		<ptr target="https://doi.org/10.1016/j.ejphar.2016.11.013PMID" />
	</analytic>
	<monogr>
		<title level="j">European journal of pharmacology</title>
		<imprint>
			<biblScope unit="volume">808</biblScope>
			<biblScope unit="page">27851904</biblScope>
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Alexithymia and its relationships with inflammatory response mediated by IL-1 family members</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Conti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Caraffa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Kritas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Ronconi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Fulcheri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of biological regulators and homeostatic agents</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="21" to="28" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Comparison of the interleukin-1β-inducing potency of allergenic spores from higher fungi (basidiomycetes) in a cryopreserved human whole blood system</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><forename type="middle">E</forename><surname>Rivera-Mariani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Vysyaraju</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Negherbon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Levetin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">E</forename><surname>Horner</surname></persName>
		</author>
		<idno type="doi">10.1159/000357036PMID</idno>
		<ptr target="https://doi.org/10.1159/000357036PMID" />
	</analytic>
	<monogr>
		<title level="m">International archives of allergy and immunology</title>
		<imprint>
			<date type="published" when="2014" />
			<biblScope unit="volume">163</biblScope>
			<biblScope unit="page">24356469</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<monogr>
		<title level="m" type="main">Suppression of inflammation and acquired immunity by IL-37. Immunological reviews</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Cavalli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">A</forename><surname>Dinarello</surname></persName>
		</author>
		<idno type="doi">10.1111/imr.12605PMID</idno>
		<ptr target="https://doi.org/10.1111/imr.12605PMID" />
		<imprint>
			<date type="published" when="2018" />
			<biblScope unit="volume">281</biblScope>
			<biblScope unit="page">29247987</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Impact of Fungi on Immune Responses</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Conti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Tettamanti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Mastrangelo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Ronconi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Frydas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clinical therapeutics</title>
		<imprint>
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">IL-37 suppresses MyD88-mediated inflammatory responses in human aortic valve interstitial cells</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Q</forename><surname>Zhan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Q</forename><surname>Zeng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Zhai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Xu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Molecular Medicine</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page">28362018</biblScope>
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">IL-37 Expression is Upregulated in Patients with Tuberculosis and Induces Macrophages Towards an M2-like Phenotype</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chi</forename><forename type="middle">X</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">W</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename></persName>
		</author>
		<idno type="doi">10.1111/sji.12326PMID</idno>
		<ptr target="https://doi.org/10.1111/sji.12326PMID" />
	</analytic>
	<monogr>
		<title level="j">Scand J Immunol</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="page">26073153</biblScope>
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Obstacles and opportunities for understanding macrophage polarization</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">J</forename><surname>Murray</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">A</forename><surname>Wynn</surname></persName>
		</author>
		<idno type="doi">10.1189/jlb.0710409PMID</idno>
		<ptr target="https://doi.org/10.1189/jlb.0710409PMID" />
	</analytic>
	<monogr>
		<title level="j">Journal of leukocyte biology</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="page">21248152</biblScope>
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Autocrine IL-10 induces hallmarks of alternative activation in macrophages and suppresses antituberculosis effector mechanisms without compromising T cell immunity</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Schreiber</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Ehlers</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Heitmann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Rausch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Mages</surname></persName>
		</author>
		<idno type="doi">10.4049/jimmunol.0803567PMID</idno>
		<ptr target="https://doi.org/10.4049/jimmunol.0803567PMID" />
	</analytic>
	<monogr>
		<title level="j">The Journal of Immunology</title>
		<imprint>
			<biblScope unit="volume">183</biblScope>
			<biblScope unit="page">19561100</biblScope>
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">C</forename><surname>El Kasmi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">E</forename><surname>Qualls</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">T</forename><surname>Pesce</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">M</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">W</forename><surname>Thompson</surname></persName>
		</author>
		<idno type="doi">10.1038/ni.1671PMID</idno>
		<ptr target="https://doi.org/10.1038/ni.1671PMID" />
	</analytic>
	<monogr>
		<title level="j">Nature immunology</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">18978793</biblScope>
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Interleukin 35: A novel candidate biomarker to diagnose early onset sepsis in neonates</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W-X</forename><surname>Du</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H-Y</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ai</forename><forename type="middle">Q</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J-L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clinica Chimica Acta</title>
		<imprint>
			<biblScope unit="volume">462</biblScope>
			<biblScope unit="page" from="90" to="95" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">IL-35 inhibits HBV antigen-specific IFN-γ-producing CTLs in vitro</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Tian</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Q</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clinical Science</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="page">25869609</biblScope>
			<date type="published" when="2015" />
			<publisher>PMID</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Nocardia brasiliensis: in vitro and in vivo growth response to steroid sex hormones</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Hernández-Herná Ndez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Ló Pez-Martínez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">J</forename><surname>Méndez-Tovar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Manzano-Gayosso</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mycopathologia</title>
		<imprint>
			<biblScope unit="volume">132</biblScope>
			<biblScope unit="page">8819830</biblScope>
			<date type="published" when="1995" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">A new model for management of mycetoma in the Sudan</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Fahal</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ame</forename><surname>Hassan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">E</forename><surname>Abdel-Rahman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Alshambaty</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Hashim</surname></persName>
		</author>
		<idno type="doi">10.1371/journal.pntd.0003271PMID</idno>
		<ptr target="https://doi.org/10.1371/journal.pntd.0003271PMID" />
	</analytic>
	<monogr>
		<title level="j">PLoS neglected tropical diseases</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">25356640</biblScope>
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">The Surgical Treatment of Mycetoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">H</forename><surname>Suleiman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Wadaella El S</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">H</forename><surname>Fahal</surname></persName>
		</author>
		<idno type="doi">10.1371/journal.pntd.0004690PMID</idno>
		<ptr target="https://doi.org/10.1371/journal.pntd.0004690PMID" />
	</analytic>
	<monogr>
		<title level="j">PLoS Negl Trop Dis</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">27336736</biblScope>
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Predictors of Post-operative Mycetoma Recurrence Using Machine-Learning Algorithms: The Mycetoma Research Center Experience</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Wadal</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">A</forename><surname>Elhassan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">A</forename><surname>Zein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Abdel-Rahman</forename><surname>Me</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">H</forename><surname>Fahal</surname></persName>
		</author>
		<idno type="doi">10.1371/journal.pntd.0005007PMID</idno>
		<ptr target="https://doi.org/10.1371/journal.pntd.0005007PMID" />
	</analytic>
	<monogr>
		<title level="j">PLoS Negl Trop Dis</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">27798643</biblScope>
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">The effects of the antifungal azoles itraconazole, fluconazole, ketoconazole and miconazole on cytokine gene expression in human lymphoid cells</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Friccius</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Pohla</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Adibzadeh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Siegels-Hubenthal</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Schenk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Immunopharmacol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">1380951</biblScope>
			<date type="published" when="1992" />
			<publisher>PMID</publisher>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
